news
New painless vaccine technology targets viruses
Learn how Kindeva and Emervax are advancing vaccine delivery with painless, needle-free technology designed to improve accessibility and uptake worldwide.
List view / Grid view
Drug Delivery
Drug delivery refers to approaches for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effect.
webinar
Advancing obesity drug discovery: Cell-based assays for GLP-1 and the G-Suite
9 January 2025 | By Eurofins DiscoverX
Discover innovative and validated solutions for developing obesity therapeutics. These solutions enable effective screening, characterisation, and potency testing for commercial lot release of novel drugs targeting GPCRs, including GLP-1, GIP, and glucagon receptors.
news
Non-invasive eye drops provide new solution for dry AMD patients
A new peptide-based eye drop treatment for dry AMD offers a non-invasive, effective alternative to injectable therapies, enhancing patient convenience and care.
news
Engineers target neurons with modified lipid nanoparticles
Researchers at the University of Pennsylvania have engineered lipid nanoparticles to target neurons, advancing mRNA treatments for brain diseases.
news
Halozyme’s €2 billion bid to transform drug discovery
By acquiring Evotec, Halozyme aims to enhance drug discovery and delivery, driving substantial growth in the pharmaceutical sector.
news
New DNA nanostructures set to transform cancer treatment
A University of Sydney study reveals how DNA origami can build programmable nanostructures, with promising applications in targeted drug delivery and nanorobotics.
news
Blood-brain barrier breakthrough for ALS and Alzheimer’s disease
A new blood-brain barrier-crossing platform enables the delivery of therapeutic molecules to the brain, offering potential treatments for ALS and Alzheimer’s disease.
article
Combining precision bispecific antibodies with targeted radiotherapy
Radioimmunotherapy (RIT) is a promising cancer treatment gaining recognition in precision oncology. It utilises radiolabelled antibodies to deliver targeted radiation to tumours, with success in hematologic cancers. However, its use in solid tumours has been limited by off-target radiation and toxicity, with few clinical trials advancing beyond phase II. Alexander…
news
Elucidating the aggregation rules for short peptides
The findings could aid the design of more stable drugs and improve the understanding of diseases linked to peptide aggregation.
podcasts
Combatting disease with antibody drug conjugates
Tune into this episode where we investigate how antibody drug conjugates can be optimised, as well as the future of the field.
news
New two-step vaccination strategy for influenza
The novel strategy demonstrates a strong immune response, both body-wide and specifically in the upper respiratory tract, in porcine models.
news
Prime editing corrects the CFTR gene mutation
The approach precisely and durably corrects the CFTR mutation in human lung cells, which could lead to superior treatments.
news
Improving vaccine responses by targeting IL-10
In an animal model, scientists have demonstrated that targeting Interleukin-10 during vaccine delivery enhances the vaccine’s ability to protect against infection.
news
Mitigating fibrotic barriers in pancreatic cancer
A human pancreatic cancer fibrotic barrier model illuminates how targeting the TGFβ/ROCK2/YAP signalling axis could enhance drug delivery.
article
Women in Stem with Dr Rachel Lagiakos
Dr H. Rachel Lagiakos is a Senior Principal Scientist in the Therapeutics Group at Schrödinger which she joined in 2018. She completed her PhD in Synthetic Organic Chemistry at Monash University and began her medicinal chemistry career at Cancer Therapeutics (CTx) in Melbourne, Australia in 2012. At CTx, Rachel’s contributions…